Evidence map›Paper›PMID 16683218›Full record

Trial reportJournal of thrombosis and thrombolysis2006

What are the barriers to warfarin use in atrial fibrillation?: Development of a questionnaire.

Anders Ingelgård, Jennifer Hollowell, Prabashni Reddy, Karen Gold, Kimbach Tran, David Fitzmaurice

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 46 citations in OpenAlex.

  1. Warfarin discontinuation after starting warfarin for atrial fibrillation.Circulation. Cardiovascular quality and outcomes · 2010
    Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Transitions of care in anticoagulated patients.Journal of multidisciplinary healthcare · 2013
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Warfarin pharmacogenetics.Pharmacotherapy · 2008
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Anders IngelgårdClinical Science, AstraZeneca, R&D Mölndal, SE-431 83, Mölndal, Sweden. Anders.ingelgard@astrazeneca.com
Jennifer Hollowell
Prabashni Reddy
Karen Gold
Kimbach Tran
David Fitzmaurice
Abt Global (United States) · USAstraZeneca (Sweden) · SEUniversity of Birmingham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite evidence of their benefit and efforts to increase usage, anticoagulation for stroke prophylaxis in atrial fibrillation (AF) patients remains underutilized. Previous surveys have assessed reasons for underuse of anticoagulation but have limitations including non-structured approach for eliciting barriers and use of clinical vignettes and not patient-level data. The objectives of this study were to develop a questionnaire to assess barriers to anticoagulation use for stroke prophylaxis in AF patients at a patient- and physician-level and to conduct a preliminary field-test of the instrument.

methodsBarriers to warfarin use were identified from a literature review, input from clinical experts, and a physician focus group. A sample of US physicians who treat AF patients completed the questionnaire. Physicians ranked their reluctance on a 1-10 scale (10 = very reluctant) in general to prescribe warfarin if a specific barrier was present in a patient and then indicated critical barriers to prescribing warfarin in a sample of their own AF patients not receiving warfarin.

resultsForty-one barriers to warfarin use were identified and classified into 4 groups: patient medical characteristics (n = 17), health care system factors (n = 7), patient capability (n = 12), and patient preference (n = 5). Several new items were developed (e.g., difficulty in obtaining venous access), existing items were revised (e.g., timeframe for bleeding episodes subdivided into > or <or= 3 months), and multi-factorial barriers (e.g., dementia, epilepsy) were explored. The factor that most strongly influenced physicians' (n = 30) decisions not to prescribe warfarin was severe bleeding < 3 months ago (mean +/- SD: 9.2 +/- 1.3) while the most prevalent critical barriers to prescribing warfarin in specific AF patients (n = 24) was patient unwilling to undergo repeat testing (29%).

conclusionThis questionnaire has the potential to assist in better understanding barriers to warfarin use with a view to addressing and then overcoming warfarin underutilization. Preliminary data suggest patient preference and capabilities are at least as important as medical characteristics as barriers to prescribing warfarin in AF patients.

Indexed as

Surveys and QuestionnairesWarfarinAtrial FibrillationContraindicationsHumansPatient ComplianceWarfarin

Identifiers

PMID16683218
OpenAlexW2012044604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.